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Abstract Previous studies indicate that expression of higher
gangliosides in renal cell carcinoma (RCC) is correlated with
metastatic potential, particularly in the lung. Out of five
major gangliosides in RCC, three disialogangliosides (disialo-
galactosylgloboside, IV3NeuAcIII6NeuAcLc4, and IV4Gal-
NAcIV3NeuAcIII6NeuAcLc4) bind strongly to siglec7, which is
expressed highly in monocytes and natural killer cells. Out of
other gangliosides tested, 2C6 sialylparagloboside, GD3, GD2,
and GT1b, but not other lacto- or ganglio-series gangliosides,
showed clear binding to siglec7. In view of preferential metastasis
of RCC to the lung, and binding of RCC cell line TOS-1 to lung
tissue sections as shown in our previous study, we examined
expression of siglec7 in the lung. siglec7 is expressed highly
in resident blood cells, but not in parenchymatous cells.
TOS-1 cells aggregate together strongly through adhesion with
peripheral blood mononuclear cells to form large clumps.
This suggests the possibility that such aggregates may form
embolisms of microvasculature, particularly in the lung, which
initiate metastasis. Other possible roles of higher gangliosides in
RCC in promoting metastasis and tumor progression are
discussed. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Renal cell carcinoma (RCC) is highly malignant, and dis-
tant metastasis is often already present at the time of ¢rst
diagnosis. A study of glycosphingolipids (GSLs) expressed
in RCC primary and metastatic lesions indicated a correlation
of the presence of thin-layer chromatography (TLC) slow-mi-
grating gangliosides with metastasis [1,2]. Among these gan-
gliosides, monosialogalactosylgloboside (MSGG) and disialo-
galactosylgloboside (DSGG) were previously identi¢ed from
RCC tissue extract [3]. We recently identi¢ed two additional
gangliosides from the metastatic RCC cell line TOS-1, termed
respectively IV3NeuAcIII6NeuAcLc4 (DSLc4) and IV4Gal-
NAcIV3NeuAcIII6NeuAcLc4 (GalNAcDSLc4) [4] (for struc-
tures and mAbs de¢ning them, see Table 1). Expression of
GalNAcDSLc4 and MSGG, de¢ned respectively by mAbs
RM2 and RM1 in primary RCC lesion, was correlated with
higher incidences of distant metastasis to the lymph node,
lung, and other organs [5]1.
This correlation observed in RCC is strikingly di¡erent
from the situation in some other types of cancer, in which
sialyl-Lewisx (SLex) and SLea show preferential metastasis,
possibly through binding of these epitopes to E-selectin ex-
pressed on activated endothelial cells (for review see [6,7]).
However, SLex, SLea, and their analogues are minimally ex-
pressed in RCC and have no association with RCC metastasis
[1]. There are several possibilities for ganglioside involvement
in the promotion of metastasis (see Section 4). Sialic acid
binding proteins (siglecs (sialic acid/immunoglobulin/lectin))
[8] may mediate binding of sialoglyco conjugates expressed
on tumor cells to certain target cells which express siglecs,
although sialoglycoproteins are the major targets of siglecs,
and little attention has been paid to gangliosides. One excep-
tion is myelin-associated glycoprotein, i.e. siglec4, which me-
diates myelin^neuron interaction by binding of ganglio-series
gangliosides [9]. A possible role of siglecs in mediating tumor
cell adhesion through sialoglyco conjugates expressed on tu-
mor cells has been considered. Of particular interest is siglec7,
which is expressed in natural killer (NK) cells and able to
a¡ect NK activity through binding [10,11]. We therefore
studied the binding speci¢city of siglec7 to various RCC-asso-
ciated gangliosides, as above, in comparison to other ganglio-
sides. Results and their functional implications are discussed
in this paper.
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Abbreviations: BSA, bovine serum albumin; DSLc4,
IV3NeuAcIII6NeuAcLc4 ; DSGG, disialogalactosylgloboside (V3Neu-
AcIV6NeuAcGb5); GalNAcDSLc4, IV4GalNAcIV3 NeuAcIII6Neu-
AcLc4 ; GSL, glycosphingolipid; MSGG, monosialogalactosylglobo-
side (V3NeuAcGb5); PBMC, peripheral blood mononuclear cells ;
PBS, 2.67 mM KCl, 1.47 mM K2HPO4, 138 mM NaCl, 8.1 mM
Na2HPO4W7H2O; RCC, renal cell carcinoma; siglec, sialic acid/immu-
noglobulin/lectin (Crocker et al., Glycobiology 8 (1998) v); 2C3
SnLc6, 2C3 sialylnorhexaosylceramide (VI3NeuAcnLc6); 2C3
SPG, 2C3 sialylparagloboside (IV3NeuAcnLc4); 2C6 SPG, 2C6
sialylparagloboside (IV6NeuAcnLc4); SPG, sialylparagloboside;
TLC, thin-layer chromatography; SLe, sialyl-Lewis; NK, natural kill-
er; Glycosphingolipids are abbreviated as recommended by IUPAC-
IUB (J. Biol. Chem. 257 (1982) 3347^3351, 262 (1987) 13^18). Gan-
gliosides are abbreviated according to Svennerholm (J. Lipid Res. 5
(1964) 145^155)
1 Further supplemental data on reactivity of RCC tissues with vari-
ous antibodies, including new mAb 5F3 directed to DSGG, as corre-
lated with distant metastasis, were presented by Akihiro Ito (PhD
Thesis, Tohoku University School of Medicine, Japan, 1997).
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2. Materials and methods
2.1. Glycolipids
GalNacDSLc4 and DSLc4 were prepared from the TOS-1 cell line,
derived from back metastatic lesion of an RCC patient [12]. DSGG
and MSGG were prepared from ACHN cells (human RCC cell line).
2C6 sialylparagloboside (SPG) was prepared from human colonic
adenocarcinoma, 2C3 SPG from human placenta, 2C3
sialylnorhexaosylceramide (2C3 SnLc6) from human erythrocytes,
and SLea from pancreatic cancer tissue. SLex was prepared by fuco-
sylation of SPG. GM1, GM2, GD1a, GD1b, GD3, and GT1b were
purchased from Matreya, Inc. (Pleasant Gap, PA, USA), and GD2
from Sigma (St. Louis, MO, USA).
2.2. Monoclonal antibodies
Anti-siglec7 mAb S7.7a was donated by Dr. P.R. Crocker [10].
Anti-P-selectin mAb P5A [13] and anti-type 2 chain H mAb BE2
[14] were established in our laboratory. Other mAbs directed to gan-
gliosides and their sources are listed in Table 1.
2.3. Construction of siglec7 expression plasmid
Siglec7 cDNA was cloned in two steps. First, most of the encoding
region including the carboxy-terminus was cloned by PCR using a
commercially available human lung cDNA library as the template
and primers derived from overlapping EST clones (5P primer
GACGTCTAGATCCCCGGGTGACCGTGCAAGAGGGCATGT
derived from EST clone AA344713 and 3P primer GGGGAAAGG-
GAGAGTTTGGTCATCAGGCATGCAT derived from EST clone
T48551).
The remaining 5P portion was cloned by RT-PCR using RNA from
human NK cells (puri¢ed from circulating blood using anti-CD56
conjugated to magnetic beads; Dynal Inc., Lake Success, NY,
USA) as the template. The RT reaction was primed with a siglec7
gene-speci¢c primer (CATACGAAAGAAGTAT), Superscript II
(Life Technologies, Grand Island, NY, USA) and conditions sug-
gested by the manufacturer. PCR used published sequences to derive
the 5P (GCCAAGCTTAACCCCAGATATGCTGCTG) and 3P
(TCCCGAGTTTCCTCCTGCAC) primers.
The C-terminal encoding fragment (cut with EaeI and XhoI), the N-
terminal encoding fragment (cut with HindIII and XhoI) and the
pCDM8 expression vector (cut with HindIII and XhoI) were ligated
and a clone containing the full length siglec7 sequence was selected
and con¢rmed by sequencing.
2.4. Transient transfection of full-length siglec7
COS-7 cells were plated at a density of 4U105/60-mm culture dish,
incubated overnight, transiently transfected with plasmid cDNA of
pCDM8-siglec7 or vector pCDM8 using FuGENE6 transfection re-
agent (Roche, Indianapolis, IN, USA), and incubated for 48 h prior
to the binding assay. Expression of siglec7 in COS-7 cells was deter-
mined by binding of human erythrocytes, as shown in Fig. 1 and
explained in its legend.
2.5. Binding speci¢city of siglec7-transfected COS-7 cells to various
gangliosides
Cells were detached with 0.05% trypsin and 0.53 mM EDTA,
washed with Dulbecco’s modi¢ed Eagle’s medium (DMEM), sus-
pended in 1 ml DMEM with 5 WM £uorescent dye (calcein-AM,
Molecular Probe, Eugene, OR, USA) at a concentration of 5U106/
ml, incubated for 45 min at 37‡C, washed with DMEM, and £uores-
cence-labeled cells were suspended in 1% bovine serum albumin (BSA)
in DMEM at a concentration of 5U105/ml.
Gangliosides were dissolved in ethanol (5 nmol/ml). A 50 Wl aliquot
and its serially diluted solution were added to each well of a 96-well
£at bottom polystyrene plate (Falcon 3915, Becton Dickinson, NJ,
USA), dried at 37‡C, and washed in PBS (2.67 mM KCl, 1.47 mM
K2HPO4, 138 mM NaCl, 8.1 mM Na2HPO4^7H2O). Each well was
blocked with 1% BSA in DMEM for 1 h at 37‡C, washed in PBS
three times, and added with 200 Wl of 1% BSA in DMEM and 100 Wl
of cell suspension (5U104 cells per well). The plate was incubated with
shielding light for 1 h at room temperature and then washed by the
following special procedure [15]. The plate was immersed in PBS(+)
(plus 0.9 mM CaCl2, 0.5 mM MgCl2) in a large container and £oated
Table 1
Major gangliosides present in human RCC, and monoclonal antibodies de¢ning them
(a) Donated by Reiji Kannagi [31]. (b) Saito et al. [3]. (c) Footnote 1. (d) Fukushi et al. [32]. (e) Ito et al. [4].
Fig. 1. Binding of human erythrocytes to siglec7-transfected COS-7
cells. 48 h after transfection, COS-7 cells were detached, plated on
48-well plates at a concentration of 1U105/well, and incubated for
4 h. 0.25% erythrocytes (v/v) in 1% BSA/DMEM (pH 7.4) were
added to each well, and incubated for 30 min at 37‡C. Each well
was washed with medium three times, and cells were observed by
microscopy. A: Siglec7-transfected COS-7 cells. Bar, 100 Wm. B:
Control COS-7 cells.
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upside-down for 10 min to allow non-adherent cells to fall out of the
wells. The plate was then turned rightside-up and removed from the
container. 200 Wl PBS of each well was removed and remaining cells
were lysed with 100 Wl 1% Triton X-100. A 100 Wl aliquot of each well
was transferred to a fresh 96-well plate, and the number of cells
adhered to ganglioside-coated wells was calculated based on £uores-
cence of each well quanti¢ed at 530 nm (excitation at 485 nm) on a
CytoFluor Multiwell Plate-Reader 4000 (PerSeptive BioSystem, Fra-
mingham, MA, USA).
2.6. Immunohistochemical staining of normal human lung sections
Surgically resected normal human lung tissues were donated by the
Department of Thoracic Surgery, Institute of Development, Aging,
and Cancer, School of Medicine, Tohoku University, Japan. Cryostat
sections (8 Wm) were mounted on microslides, ¢xed in cold acetone,
blocked with 1% defatted milk in PBS, and incubated with primary
antibodies overnight at 4‡C. Endogenous peroxidase was blocked with
0.3% H2O2 in PBS for 5 min. Sections were incubated with biotinyl-
ated secondary antibody for 1 h, incubated with Vector avidin^biotin
solution for 1 h, and stained with 0.05% 3,3P-diaminobenzidine and
0.01% H2O2 in 0.05 M Tris^HCl.
2.7. Aggregation of TOS-1 cells with peripheral blood mononuclear
cells (PBMC)
TOS-1 cells were detached with 0.05% trypsin and 0.53 mM EDTA,
washed, and suspended in 1% BSA in DMEM. PBMC were isolated
from heparinized blood of healthy donors by sedimentation on Ficoll-
Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ, USA) gra-
dients and labeled with £uorescent Calcein-AM as described in Sec-
tion 2.5. Labeling of lymphocytes and leukocytes by calcein-AM does
not alter cellular functions, including cell binding activity [16]. TOS-1
cells (5U105/100 Wl) and PBMC (2U106/100 Wl) were mixed, incu-
bated for 30 min at 37‡C, and observed under £uorescence microsco-
py.
3. Results
Three disialogangliosides expressed highly in RCC, i.e.
DSGG, DSLc4, and GalNAcDSLc4 (for structures see Table
1), showed strong binding to siglec7 expressed on COS-7 cells
transfected with the siglec7 gene (Fig. 2A,B). Clear cell bind-
ing was observed for 8^16 pmol/well of these three ganglio-
sides. In contrast, clear antibody binding was observed for
0.8^1.6 pmol/well of the same gangliosides. MSGG and
GM2, both expressed highly in RCC, did not show clear bind-
ing to siglec7 (Fig. 2A,D). In contrast, various disialoganglio-
sides with ganglio-series structure, i.e. GD3, GT1b, GD2,
showed strong binding (Fig. 2D). GD1a, GD1b, GM1,
SLex, and SLea showed no binding (Fig. 2B,D). Among
type 2 lacto-series gangliosides, 2C6 SPG showed strong
binding, whereas 2C3 SPG and 2C3 SnLc6 showed no bind-
ing (Fig. 2C). In these experiments, binding activity and spe-
ci¢city of various gangliosides were highly reproducible when
using COS-7 cells with comparable degree of siglec7 expres-
sion.
Because lung tissue is the most frequent site of RCC meta-
stasis, we previously studied binding of RCC-derived TOS-1
cells to various frozen tissue sections [17] by the Stamper^
Woodru¡ method [18] and found that TOS-1 cells showed
preferential binding to the perialveolar area of lung tissue.
In addition, the siglec7 messenger was reported to be ex-
pressed in the lung [10,19], and we con¢rmed this observation.
A possibility is therefore suggested that TOS-1 cell binding to
lung tissue is due to expression of siglec7 in the normal lung.
However, lung tissue contains numerous monocytes, macro-
phages, and other types of leukocytes, which are known to
express high levels of various siglecs, including siglec7 [10]. We
con¢rmed that anti-siglec7 mAb S7.7a strongly stained blood
cells. We therefore studied expression of siglec7 in parenchym-
atous cells of normal lung tissue. mAb S7.7a did not immu-
nostain endothelial cells, bronchioli, or other parenchymatous
cells (Fig. 3, panel 1C), whereas positive staining was observed
for control markers (P-selectin for endothelial cells ; H-antigen
for bronchioli) (Fig. 3, panels 1A,B). When TOS-1 cells were
incubated with £uorescence-labeled PBMC, as described in
Section 2, they aggregated together to form clumps (Fig. 3,
Fig. 2. Binding speci¢city of siglec7-transfected COS-7 cells to vari-
ous gangliosides. 48 h after transfection, detached COS-7 cells were
labeled with calcein-AM, and suspended in 1% BSA in DMEM at a
concentration of 5U105/ml. Serially diluted gangliosides were coated
to 96-well £at bottom polystyrene plates (approximate quantity in
pmol per well is shown on abscissa). After blocking with 1% BSA
in DMEM, 100 Wl of cell suspension (5U104 cells per well) was
added, incubated for 1 h at room temperature with shielding light,
and the plate was washed as described in the text. Adherent cells
were lysed with 1% Triton X-100, and £uorescence of each well was
quanti¢ed at 530 nm (excitation at 485 nm). Each point represents
mean value of three separate experiments using COS-7 cells with
similar degrees of siglec7 expression. Vertical bar, standard varia-
tion. A: Globo-series gangliosides. B: Lacto-series type 1 chain gan-
gliosides. C: Neolacto-series type 2 chain gangliosides. D: Ganglio-
series gangliosides.
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panel 2) or larger mixed clumps in which tumor cell aggre-
gates are covered by PBMC (inset of Fig. 3, panel 2).
4. Discussion
Previous studies suggested that RCC metastasis is corre-
lated with expression of disialogangliosides having an ex-
tended globo-series core, DSGG [3], or lacto type 1 chain
core, DSLc4 or GalNAcDSLc4 [4]. We demonstrate in this
paper that: (i) these gangliosides highly expressed in RCC
bind strongly to siglec7 expressed on COS-7 cells, (ii) RCC
cell line TOS-1 binds to PBMC and other types of blood cells
expressing siglec7, leading to aggregation of TOS-1 cells to
form large clumps under physiological conditions, (iii) siglec7
expression in lung tissue is due to resident blood cells, whereas
siglec7 is absent in parenchymatous lung tissue including en-
dothelial cells of vasculature (marked by P-selectin), bronchio-
li (marked by H-antigen), and connective tissues. Siglec7 mes-
sengers are expressed in various organs including the lung [10]
and we con¢rmed this ¢nding. This is ascribable to the pres-
ence of resident blood cells, as described previously [19].
These observations suggest the possibility that RCC meta-
stasis may be mediated by tumor cell aggregation with PBMC
and other types of blood cells, and that such clumps may
cause embolisms of microvasculature, particularly in the
lung. This mechanism may occur in various types of tumor
cells besides RCC, mediated by other siglecs besides siglec7. In
normal blood (not heparinized blood used in experiments)
tumor cell aggregates may include platelets which are acti-
vated by tumor cells to release a factor or factors. The factors
in turn activate endothelial cells to elicit ICAMs, VCAMs, or
E- or P-selectin, which initiate tumor cell adhesion or invasion
[20,21]. However, in the case of RCC metastasis, the role of
SLex and SLea through their binding to selectin is negligible
[17] in contrast to many other types of tumors [6,7].
A few other functional roles of gangliosides in tumor pro-
gression can be considered: (i) tumor cell binding to endothe-
lial cells is mediated by speci¢c carbohydrates, either by in-
teraction of SLex, SLea, or myeloglycan-type with E-selectin
[15], or by binding of speci¢c gangliosides highly expressed in
tumor cells to endothelial cell GSLs through carbohydrate^
carbohydrate interaction, a typical example being the interac-
Fig. 3. Immunohistochemical staining of siglec7 expressed in normal
human lung frozen sections, and typical aggregates of RCC-derived
TOS-1 cells with PBMC. 1A: Staining with anti-type 2 chain H
mAb BE2; indicates mucous membrane (bronchiolus). Bar, 100 Wm.
1B: Staining with anti-P-selectin P5A; indicates endothelial cells.
1C: Staining with anti-siglec7 S7.7a. No staining is seen in paren-
chymatous tissue. Areas with presence of resident blood cells are
omitted. 2: TOS-1 cells (large cells) and PBMC labeled with calcein-
AM (small green £uorescent cells) were mixed, and incubated for 30
min at 37‡C. Cells were observed under £uorescence microscopy. In-
set, one of the typical large clumps (tumor cell aggregate sur-
rounded by PBMC) occasionally observed.
Fig. 4. Possible functional roles of gangliosides in tumor cell meta-
stasis/invasion. Four categories of processes are illustrated. A: Pro-
cesses based on tumor cell clumping through interaction of tumor
cells with PBMC or other blood cells, leading to microembolism.
Clumping in normal blood in vivo may include platelets. Both
platelets and PBMC, when activated, release factors that activate
endothelial cells (EC) and promote tumor cell migration to initiate
metastasis (this paper). B: Processes based on tumor cell adhesion
to EC without clumping or microembolism. Activation of platelets
(P) or lymphocytes (L) induces factors (F) to activate EC [20,21],
similar to process A. However, in this case, tumor cell adhesion to
EC is based on selectin [6,7,15], integrin^tetraspanin complex [23^
25] that binds to ICAM or VCAM, or carbohydrate^carbohydrate
interaction [22]. Cell adhesion/motility controlled by integrin com-
plexed with tetraspanin (CD9 or CD82) is strongly modulated by
gangliosides [25]. C: Processes based on ganglioside-dependent sup-
pression of immunocytes. Gangliosides on the cell surface, or shed
from cells, suppress (i) cytotoxic T-cells [28,29] or (ii) NK cells [11].
D: Processes based on modulation of tumor-associated angiogenesis,
e.g. GD3 or GM2 promotes angiogenesis [26,27]. A possible mecha-
nism is e¡ect of these gangliosides on vascular endothelial growth
factor receptor function.
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tion of GM3 (highly expressed on B16 melanoma cells) with
LacCer or Gb4 (expressed on endothelial cells) [22], (ii) tu-
mor-associated GSLs modulate adhesion receptors (e.g. integ-
rins) or tetraspanin, to enhance tumor cell adhesion and mo-
tility [23^25], (iii) certain gangliosides such as GM2 or GD3
promote tumor-associated angiogenesis [26,27], (iv) tumor-as-
sociated gangliosides act as immunosuppressors, as typically
observed for suppression of cytotoxic T-cells [28,29], and pos-
sible inhibition of NK cells by binding of tumor-associated
gangliosides to siglec7 [11]. Possible functional roles of gan-
gliosides in tumor cell metastasis/invasion are illustrated in
Fig. 4 and its legend.
Siglecs were discovered originally as ‘sialoadhesin’ by
Crocker and associates. The number of known members of
the ‘siglec family’ has increased greatly through cloning based
on the original sequence. They are accordingly expressed in
various types of blood cells, including NK cells. Some siglecs
have been shown to bind preferentially to sialyl 2C6 Gal, as
originally observed for CD22 (siglec2) [30]. Similar preferen-
tial binding to sialyl 2C6 Gal was found for siglec7 [19].
Binding of 2C6 SPG but not 2C3 SPG to siglec7, as indi-
cated in the present study, con¢rmed these previous results.
Interestingly, DSLc4, GalNAcDSLc4, and DSGG, which bind
strongly to siglec7 and are expressed highly in RCC, are char-
acterized by having sialyl 2C6 GlcNAc or sialyl 2C6 Gal-
NAc. GD3, GD2, and GT1b are expressed highly in numer-
ous types of tumors [6] and are capable of binding to siglec7
(as shown in the present study). Therefore, these disialo epi-
topes may promote metastasis through a mechanism involving
microembolisms, similar to that discussed above, or by other
possible mechanisms as illustrated in Fig. 4.
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